Ra Capital Management Reveals New Stake in Enanta Pharmaceuticals Inc (ENTA)

Peter Kolchinsky‘s Ra Capital Management disclosed a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). According to a 13G filing, the new positions amounts to 1.54 million shares, which represent 8.00% of the company’s common stock. 

Peter Kolchinsky

Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a biotechnology company focused on the research and development of small molecule drugs in the infectious disease field. The company aims to discover and develop novel inhibitors designed for use against the HCV (hepatitis C virus). In addition to the HCV programs, Enanta has created Bicyclolides - a class of antibiotics for the treatment of multi-drug-resistant bacteria. In March, 2013, the drug developer raised $56.00 million in an initial public offering, pricing the stock at $14.00 per share.  The same year, the company disclosed net losses of slightly more than $4.00 million with respective losses of $0.67 per share, beating market expectations ($-1.78) by more than 60.00%. Analysts estimate steady earnings growth for the period of 2014, predicting losses per share of $0.30 for the first quarter, but earnings per share of $1.45 for the whole year. In 2015, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is expected to produce profits per share in the range of $3.00 to a high $16.00 per share. Average consensus recommendation for the company’s stock is “Buy”.

Managed by Mitchell Blutt, Consonance Capital Management is another large shareholder at Enanta Pharmaceuticals, holding more than 850,000 shares of the company as at the end of 2013 – a position worth $23.20 million.

A graduate from Harvard with a Ph.D. in virology, Peter Kolchinsky manages an equity portfolio concentrated almost entirely in the Healthcare Sector. The largest position in the portfolio (15.30%) belongs to Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), in which Kolchinsky’s fund invested $77.60 million, holding nearly 23.40 million shares.

Recently, RA Capital disclosed a new passive stake of 1.44 million shares in Repros Therapeutics Inc (NASDAQ:RPRX). Also, the fund boosted its position in pSivida Corp. (NASDAQ:PSDV) to 2.56 million shares – 6.20% of the company’s common stock.

Disclosure: none

Recommended Reading:

Ra Capital Management Initiates Stake in Furiex Pharmaceuticals Inc (FURX) After the Stock Jumped

Ra Capital Management Lowers Stake in Derma Sciences Inc (DSCI)

Trian Partners Discloses an Increased Position in Ingersoll-Rand PLC (IR)

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!